Related Content
- New alliance will crack down on adulterated products touting dietary supplement claims
- FDA approves test to monitor levels of Zortress in the bloodstream
- FDA approves Merck's Gardasil for prevention of anal cancer
- Merck's hepatitis C drug granted priority review by FDA
- Report: Sharfstein to leave FDA
SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Celgene for treating the cancer multiple myeloma, the agency said Friday.
The FDA announced the approval of Pomalyst (pomalidomide) for patients whose disease has progressed after treatment with other cancer drugs.
Multiple myeloma is a form of blood cancer that mostly affects older people and comes from plasma cells in the bone marrow. About 21,700 Americans are diagnosed with it, and 10,710 die every year from the disease, according to the National Cancer Institute.
